Artificial Intelligence

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Elsevier #Research and development #Survey

Report says many R&D companies have based decisions on flawed data

R&D teams are confident in their evidence, yet report making decisions based on flawed or incomplete data, according to Elsevier’s Corporate R&D of the Future report.  The report is based on a global survey of more than 1,000 R&D leaders, managers and researchers at R&D-led corporations. … Read More

#Editor's Choice #News

#Artificial intelligence (AI) #Funding #Mouse models #PhaSER Biomedical (PhaSER)

 PhaSER receives $2.7 million to grow company

Biotechnology company PhaSER Biomedical has received $2.7 million from the Gates Foundation as part of a two-year grant renewal.  The Scottish-based company will use the funding to support the discovery of new treatments targeting some of the world’s most neglected diseases.   The funding continues PhaSER’s… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Automation / robotics #Collaboration #Drug discovery #Pierre Fabre #XtalPi

Pierre Fabre and XtalPi team up on drug discovery

Pharmaceutical company Laboratoires Pierre Fabre and AI platform company XtalPi have announced a collaboration to discover novel drug candidates across oncology, rare diseases, and dermatology.  Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Therapeutic Antibodies

From AI design to experimental validation: The next frontier in antibody discovery

This article is sponsored by GenScript. Integration of artificial intelligence (AI) into antibody drug discovery is occurring in phases, as AI models mature, and developers seek to compress discovery and development timelines. While increasingly iterative and feedback-driven approaches to AI-driven antibody discovery have made the process more efficient,… Read More

#Exclusive Content

#ALLOX #Artificial intelligence (AI) #Drug discovery #Financing #Seed funding

ALLOX closes $10.5m financing to scale allosteric discovery platform

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.   The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC… Read More

#Business & Investment #News #Start-up Zone

#Artificial intelligence (AI) #Automation / robotics #Financing #Opentrons

Opentrons announces $40m Series E funding round

Opentrons Labworks has announced a $40 million Series E financing led by healthcare investor Avego, with additional investment from BroadOak Capital Partners.   Opentrons says it will use the capital to scale its robotics, software, and data infrastructure tools.  While AI is transforming how science is… Read More

#Business & Investment #News

#ADME / Tox #Artificial intelligence (AI) #AstraZeneca #Collaboration #Drug safety #Tremont AI

Research collab will build AI solutions for accelerated safety screening

AstraZeneca and Tremont AI have announced a research collaboration to develop and evaluate AI solutions for accelerated safety screening in preclinical toxicologic pathology studies.  Assessing the safety of a new drug is one of the most demanding steps before it can reach patients.  Toxicologic pathologists… Read More

#News

#Artificial intelligence (AI) #Immunology / Virology & Vaccines #NEC Bio #Pandemic response

EU project strengthens pandemic preparedness with AI vaccine design

PREPAIR VAC is a Horizon Europe-funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design.  NEC Corporation’s NEC OncoImmunity (NOI) will be working alongside several European partners comprising a research consortium.  The four-year research grant beginning in… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical research #Clinical trials #Data standardisation #Drug discovery

The evolution of AI agents in drug discovery

Partha Anbil and Satish Tadikonda explore the current state of AI agents in drug discovery, with a specific focus on clinical data harmonisation, the transition to autonomous laboratories, and the projected market growth that underscores this technological revolution.  Introduction: The dawn of agentic AI  Drug… Read More

#Exclusive Content

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Last chance to register: How AI agents are accelerating R&D

R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #FAIR Principles

Building strong data foundations for multimodal drug discovery

As drug discovery spans more modalities and more AI driven workflows, research teams face a growing challenge in keeping data connected and meaningful as it moves between people, systems and organisations. Here, Janice Darlington, Director of Customer Engagement at Collaborative Drug… Read More

#Exclusive Content

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Webinar: How AI agents are accelerating R&D

R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More

#News

#Artificial intelligence (AI) #AstraZeneca #Cardiometabolic diseases #Collaboration

AZ signs AI drug discovery deal with insitro

AstraZeneca and insitro have signed a worldwide exclusive research collaboration agreement to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.   Under the terms of the agreement, insitro will receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and… Read More

#Business & Investment #News